Coronary Sinus Metabolite 12,13-diHOME Is a Novel Biomarker for Left Atrial Remodeling in Patients With Atrial Fibrillation

Xixiang Tang; Jiafu Wang; Xiaolan Ouyang; Qian Chen; Ruimin Dong; Yanting Luo; Junlin Zhong; Zhuoshan Huang; Long Peng; Xujing Xie; Jieming Zhu; Zhenda Zheng; Suhua Li

doi:10.1161/CIRCEP.123.012486

Coronary Sinus Metabolite 12,13-diHOME Is a Novel Biomarker for Left Atrial Remodeling in Patients With Atrial Fibrillation

Circ Arrhythm Electrophysiol. 2024 May 1:e012486. doi: 10.1161/CIRCEP.123.012486. Online ahead of print.

Authors

Xixiang Tang^#¹, Jiafu Wang^#², Xiaolan Ouyang^#², Qian Chen², Ruimin Dong², Yanting Luo², Junlin Zhong³, Zhuoshan Huang², Long Peng², Xujing Xie², Jieming Zhu², Zhenda Zheng², Suhua Li²

Affiliations

¹ VIP Medical Service Center, Sun Yat-sen University, Guangzhou, China. (X.T.).
² Department of Cardiovascular Medicine, Sun Yat-sen University, Guangzhou, China. (J.W., X.O., Q.C., R.D., Y.L., Z.H., L.P., X.X., J.Z., Z.Z., S.L.).
³ Department of Ultrasonography, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. (J.Z.).

^# Contributed equally.

PMID: 38690652
DOI: 10.1161/CIRCEP.123.012486

Abstract

Background: 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) has shown potential in protecting against heart disease, but its relationship with atrial fibrillation (AF) remains unknown.

Methods: Coronary sinus (CS) and femoral vein blood samplings were synchronously collected from AF and non-AF subjects (paroxysmal supraventricular tachycardia or idiopathic premature ventricular complexes) who underwent catheter ablation. First, untargeted metabolomic profiling was performed in a discovery cohort (including 12 AF and 12 non-AF subjects) to identify the most promising CS or femoral vein metabolite. Then, the selected metabolite was further measured in a validation cohort (including 119 AF and 103 non-AF subjects) to confirm its relationship with left atrium remodeling and 1-year postablation recurrence of AF. Finally, the biological function of the selected metabolite was validated in a rapid-paced cultured HL-1 atrial cardiomyocytes model.

Results: Metabolomic analysis identified CS 12,13-diHOME as the most pronounced change metabolite correlated with left atrium remodeling in the discovery cohort. In the validation cohort, CS 12,13-diHOME was significantly lower in patients with AF than non-AF controls (84.32±20.13 versus 96.24±23.56 pg/mL; P<0.01), and associated with worse structural, functional, and electrical remodeling of left atrium. Multivariable regression analyses further demonstrated that decreased CS 12,13-diHOME was an independent predictor of 1-year postablation recurrence of AF (odds ratio, 0.754 [95% CI, 0.648-0.920]; P=0.005). Biological function validations showed that 12,13-diHOME treatment significantly protect the cell viability, improved the expression of MHC (myosin heavy chain) and L-type calcium channel α1c, and attenuated mitochondrial damage in the rapid-paced cultured HL-1 cardiomyocytes model.

Conclusions: CS metabolite 12,13-diHOME is decreased in patients with AF and can serve as a novel biomarker for left atrium remodeling.

Keywords: atrial fibrillation; blood pressure; coronary sinus; hypertension; metabolite.